Argos Therapeutics, Inc.

4233 Technology Drive Durham, NC 27704

Argos Therapeutics is a pioneer in immunotherapy. Our focus is bringing to market therapeutic options that not only offer new promise for treatment of intractable diseases, but also an improved safety profile and better patient quality of life during treatment. By combining proprietary knowledge of dendritic cell behavior and enabling presentation of relevant antigens via RNA, Argos’ vaccine therapies unlock the potential of an individual’s own body, retraining the immune system to recognize and target disease at its cellular origin. Our technology has strong application for cancer and other clinical challenges, including infectious disease, autoimmune disorders and transplantation.

Biolex, Inc.

158 Credle Street, Pittsboro, NC 27312

Biolex is developing recombinant human therapeutic proteins that, until now, have been impossible or very expensive to develop in existing protein expression systems. Biolex utilizes the LEX System™, Biolex' transformational development and production technology for these hard-to-make proteins. The LEX System™ has been shown to significantly enable faster, less-expensive development and production of hard-to-make proteins (such as peptides and cytokines) and monoclonal antibodies (mAbs). The company has a strong patent position, an FDA-agreed production approach and top-level management with extensive industry experience in therapeutic proteins. Biolex is developing its own pipeline of hard-to-make proteins and monoclonal antibodies, and is establishing partnerships with a number of top-tier pharmaceutical and biotechnology companies.

CellzDirect
*VENDOR/SERVICE*

480 Hillsboro St., Suite 130, Pittsboro NORTH CAROLINA 27312 1624 Headway Circle, Suite 100, Austin TEXAS 78754

CellzDirect is a biotech company providing in vitro hepatic cell products and contract laboratory and consulting services to drug discovery and development scientists worldwide. We offer a complete line of high quality fresh hepatocytes, cryopreserved hepatocytes and liver subcellular fractions. Our service offerings include drug-drug interaction studies, drug metabolism studies, and hepatotoxicity assays in both GLP and non-GLP formats. With CellzDirect’s support, scientists are better able to conduct research that accelerates the discovery of safe and effective drugs.

Chimerix, Inc.

5007 Southpark Drive, Suite 200 Durham, NC 27713

Chimerix discovers, develops and commercializes therapeutics with enhanced pharmaceutical properties that are active against a broad range of viral diseases. Leveraging a powerful lipid prodrug technology, ProLipTagTM, Chimerix is able to develop drug candidates with oral-availability, increased potency and targeted delivery. These enhanced pharmaceutical properties can be applied to new drug moieties or known drugs to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse reactions.

Eisai Inc.

100 Tice Blvd.,Woodcliff Lake, NJ 07677 900 Davis Drive, P.O. Box 14505, Research Triangle Park, NC 27709

Eisai's research and development emphasis is on four therapeutic areas - neurology, gastrointestinal disorders, cancer and acute care. The company has three products on the U.S. market. These include treatments for: Alzheimer's disease, gastrointestinal disorder, and status epilepticus -- a condition in which one major convulsive attack follows another with little or no intermission. Eisai Inc. is supported by a strong parent company, Eisai Co., Ltd.

Gentris

133 Southcenter Court, Suite 400, Morrisville, NC 27560

Gentris Corporation will lead the new paradigm in healthcare by enabling the administration of medication based on individual genetic variation by offering high quality pharmacogenomic laboratory testing services and diagnostic products.

Gilead Sciences, Inc
(GILD) 33.91

333 Lakeside Drive, Foster City, CA 94404 4 University Place 4611 University Drive Durham, NC 27707 650 Cliffside Drive, San Dimas, CA 91773 2025 1st Avenue, Suite 800, Seattle, WA 98121 7575 W. 103rd Avenue, Suite 102, Westminster, CO 80021

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide.

Icagen
(ICGN) 0.24

4222 Emperor Blvd., Suite 350, Durham, NC 27703

Icagen is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads.

Inspire Pharmaceuticals, Inc.
(ISPH) 4.90

4222 Emperor Boulevard, Suite 200, Durham, NC 27703

Inspire is a biopharmaceutical company focused on discovering, developing and commercializing new treatments for diseases in the ophthalmic and respiratory/allergy areas.

Nobex

P.O. Box 13940, Research Triangle Park NORTH CAROLINA 27709

NOBEX is a drug delivery company developing modified drug molecules to improve medications for chronic diseases. The core scientific expertise of NOBEX is applying medicinal chemistry to the challenges of drug delivery. Around this core science, NOBEX is positioned to tackle the technically difficult task of getting drug compounds to cross barriers of the body such as the gastrointestinal environment and the blood-brain-barrier of the central nervous system. NOBEX has formed partnerships with several pharmaceutical and biotechnology companies including Pharmacia, Novartis and Biomedicines to enable the oral delivery of drugs in several therapeutic areas. NOBEX has built a robust pipeline of new therapeutics primarily in three key areas of: metabolism, oncology and gastroenterology.

OncoMethylome Sciences

2505 Meridian Parkway, Suite 310, Durham, NC 27713 Tour 5 GIGA niveau +3, Av. de l’Hopital 11, 4000 Liege, BELGIUM Meibergdreef 59, 1105 BA Amsterdam, The Netherlands

OncoMethylome Sciences is a bio-tech company dedicated to developing tests for early cancer detection and personalized treatment decisions. Specifically, OncoMethylome Sciences develops DNA gene methylation tests to assist physicians (i) in detecting cancer at an early stage with a high level of accuracy and (ii) in predicting a patient’s response to cancer therapy or the likelihood of cancer recurrence.

Qualyst, Inc.

5410 Trinity Road, Suite 108, Raleigh, NC 27607-3815

Qualyst focuses on commercializing novel and proprietary ADMET products for drug discovery and development customers. Qualyst aims to provide better knowledge to researchers regarding drug candidate compounds – saving organizations valuable time and research dollars in the process.

Salix Pharmaceuticals
(SLXP) 40.35

1700 Perimeter Park Drive, Morrisville, NC 27560-8404

Our efforts are designed to identify and acquire late-stage and/or marketed proprietary pharmaceutical products for the treatment of gastrointestinal disease that have an existing base of safety and efficacy data. This focus on late-stage products serves to reduce the risk, time and expense Salix invests in products compared to the investment typically associated with the research and early development phases of pharmaceutical products.

Targacept, Inc.

200 East First Street, Suite 300, Winston-Salem, NC 27101-4165

Targacept, Inc. is engaged in the design, discovery and development of NNR Therapeutics™, a new class of drugs for the treatment of multiple diseases and disorders of the central nervous system. Our NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs.NNrs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity. We currently have four clinical-stage product candidates and three preclinical product candidates. Our most advanced product candidates are in development as treatments for cognitive impairment, depression and anxiety disorders, and pain.

Transtech Pharma

4170 Mendenhall Oaks Pkwy., High Point, NC 27265

We are a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of human therapeutics to fill unmet medical needs. Our mission is to utilize our innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines. We have a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, cardiovascular disorders, type I/II diabetes, obesity, and cancer. We have built our product candidate portfolio through internal discovery. Our lead product candidate, TTP488, is a novel, orally bioavailable compound that is being developed as a potential treatment for Alzheimer’s disease.

Tranzyme Pharma

4819 Emperor Blvd, Suite 400, Durham, NC 27703 001 12e Avenue Nord, Sherbrooke, QC, J1H 5N4, CANADA

Tranzyme Pharma is developing novel small molecules targeting key validated G protein-coupled receptors (GPCRs) that regulate gastrointestinal motility, appetite and metabolism. These GPCRs include ghrelin (responsible for upper gut motility, appetite stimulation, and energy balance) and motilin (responsible for regulation of gastrointestinal transit).

Trimeris Inc
(TRMS) 2.31

3500 Paramount Parkway, Morrisville, NC 27560

Trimeris is a biopharmaceutical company engaged in the discovery, development, and commercialization of novel medicines to treat viral diseases.

United Therapeutics Corp
(UTHR) 48.54

1110 Spring St. Silver Spring, MD 20910 One Park Drive, Fourth Floor, Research Triangle Park, NC 27709 The Surrey Research Park, 26 - 28 Frederick Sanger Road, Guildford, Surrey GU2 7YD, UK

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases. In these segments, United Therapeutics is actively developing four technology platforms: Prostacyclin Analogs, Immunotherapeutic Monoclonal Antibodies, Glycobiology, and Telemedicine.